$ENZ
ENZO BIOCHEM INC Stock $enz

$enz Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-K Financial Statement

#000121390022064086 Filed on October 14, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2022
Revenue	$18.28M	$20.28M	$107.1M
YoY Change	-31.08%	-18.25%	-9.05%
Cost Of Revenue	$14.67M	$15.94M	$65.10M
YoY Change	-3.94%	6.29%	1.48%
Gross Profit	$3.605M	$4.340M	$41.97M
YoY Change	-67.94%	-55.77%	-21.67%
Gross Profit Margin	19.73%	21.4%	39.2%
Selling, General & Admin	$11.45M	$11.06M	$48.02M
YoY Change	3.61%	-6.26%	6.93%
% of Gross Profit	317.64%	254.79%	114.42%
Research & Development	$996.0K	$1.070M	$3.767M
YoY Change	33.87%	23.84%	15.84%
% of Gross Profit	27.63%	24.65%	8.98%
Depreciation & Amortization	$780.0K	$689.0K	$2.566M
YoY Change	11.27%	0.58%	-3.28%
% of Gross Profit	21.64%	15.88%	6.11%
Operating Expenses	$9.000K	$12.13M	$51.79M
YoY Change	-99.92%	-4.2%	7.53%
Operating Profit	-$9.913M	-$7.788M	-$15.01M
YoY Change	1702.36%	173.55%	-376.88%
Interest Expense	-$727.0K	-$337.0K	-$2.063M
YoY Change	112.57%	206.36%	-842.09%
% of Operating Profit
Other Income/Expense, Net	$5.000K	$20.00K	-$1.191M
YoY Change	-103.45%	-99.86%	-108.57%
Pretax Income	-$10.64M	-$8.433M	-$18.26M
YoY Change	358.6%	-358.05%	-331.89%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$10.64M	-$8.433M	-$18.26M
YoY Change	358.6%	-358.05%	-331.89%
Net Earnings / Revenue	-58.19%	-41.57%	-17.06%
Basic Earnings Per Share	-$0.22		-$0.38
Diluted Earnings Per Share	-$0.22	-$173.1K	-$0.38
COMMON SHARES
Basic Shares Outstanding	48.72M shares		48.59K shares
Diluted Shares Outstanding	48.72K shares		48.59K shares

Balance Sheet

Concept	2022 Q4	2022 Q3	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$12.14M	$21.60M	$21.60M
YoY Change	-66.45%	-50.34%	-50.34%
Cash & Equivalents	$12.14M	$21.60M	$21.60M
Short-Term Investments		$0.00	$0.00
Other Short-Term Assets	$5.142M	$5.824M	$5.824M
YoY Change	15.37%	37.68%	37.68%
Inventory	$15.79M	$15.41M	$15.41M
Prepaid Expenses	$5.142M	$5.824M
Receivables	$11.52M	$11.52M	$11.52M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$44.58M	$54.35M	$54.35M
YoY Change	-32.37%	-22.99%	-22.99%
LONG-TERM ASSETS
Property, Plant & Equipment	$17.14M	$17.26M	$32.43M
YoY Change	-48.39%	-48.64%	-3.49%
Goodwill	$7.452M	$7.452M
YoY Change		0.0%
Intangibles		$0.00
YoY Change		-100.0%
Long-Term Investments
YoY Change
Other Assets	$1.609M	$1.618M	$1.618M
YoY Change	15.59%	-10.51%	-10.51%
Total Long-Term Assets	$40.62M	$41.50M	$41.50M
YoY Change	-3.81%	-3.73%	-3.73%
TOTAL ASSETS
Total Short-Term Assets	$44.58M	$54.35M	$54.35M
Total Long-Term Assets	$40.62M	$41.50M	$41.50M
Total Assets	$85.20M	$95.86M	$95.86M
YoY Change	-21.21%	-15.69%	-15.69%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$8.109M	$8.508M	$8.508M
YoY Change	36.77%	4.74%	4.74%
Accrued Expenses	$12.38M	$12.30M	$15.73M
YoY Change	-16.61%	-18.25%	4.57%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$228.0K	$229.0K	$310.0K
YoY Change	-2.98%	-1.72%	33.05%
Total Short-Term Liabilities	$24.25M	$24.55M	$24.55M
YoY Change	4.96%	-5.85%	-5.85%
LONG-TERM LIABILITIES
Long-Term Debt	$3.986M	$4.077M	$4.116M
YoY Change	-9.51%	-8.71%	-7.84%
Other Long-Term Liabilities	$18.00K	$39.00K	$12.73M
YoY Change	-99.87%	-99.73%	-12.59%
Total Long-Term Liabilities	$4.004M	$4.116M	$16.85M
YoY Change	-78.09%	-78.37%	-11.48%
TOTAL LIABILITIES
Total Short-Term Liabilities	$24.25M	$24.55M	$24.55M
Total Long-Term Liabilities	$4.004M	$4.116M	$16.85M
Total Liabilities	$40.21M	$41.40M	$41.40M
YoY Change	-2.83%	-8.23%	-8.23%
SHAREHOLDERS EQUITY
Retained Earnings	-$299.3M	-$288.6M
YoY Change		6.75%
Common Stock	$487.0K	$487.0K
YoY Change		0.41%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$44.99M	$54.46M	$54.46M
YoY Change
Total Liabilities & Shareholders Equity	$85.20M	$95.86M	$95.86M
YoY Change	-21.21%	-15.69%	-15.69%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2022
OPERATING ACTIVITIES
Net Income	-$10.64M	-$8.433M	-$18.26M
YoY Change	358.6%	-358.05%	-331.89%
Depreciation, Depletion And Amortization	$780.0K	$689.0K	$2.566M
YoY Change	11.27%	0.58%	-3.28%
Cash From Operating Activities	-$8.693M	-$9.070M	-$16.59M
YoY Change	43.85%	-8498.15%	-4386.82%
INVESTING ACTIVITIES
Capital Expenditures	-$652.0K	-$369.0K	-$3.472M
YoY Change	-36.88%	-76.44%	-21.73%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$28.70M
YoY Change	-100.0%	-100.0%	-195.46%
Cash From Investing Activities	-$652.0K	-$369.0K	$25.22M
YoY Change	-38.55%	-77.0%	-173.12%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$95.00K	-96.00K	-$241.0K
YoY Change	66.67%	71.43%	-0.41%
NET CHANGE
Cash From Operating Activities	-$8.693M	-9.070M	-$16.59M
Cash From Investing Activities	-$652.0K	-369.0K	$25.22M
Cash From Financing Activities	-$95.00K	-96.00K	-$241.0K
Net Change In Cash	-$9.468M	-9.535M	$8.329M
YoY Change	32.22%	514.37%	-124.25%
FREE CASH FLOW
Cash From Operating Activities	-$8.693M	-$9.070M	-$16.59M
Capital Expenditures	-$652.0K	-$369.0K	-$3.472M
Free Cash Flow	-$8.041M	-$8.701M	-$13.12M
YoY Change	60.5%	-619.77%	-371.99%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-07-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--07-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-09974
CY2022	dei	Entity Registrant Name EntityRegistrantName	ENZO BIOCHEM, INC.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NY
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	13-2866202
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	81 Executive Blvd
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 3 Farmingdale
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	NY
CY2021Q3	us-gaap	Goodwill Goodwill	7452000	usd
CY2021Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	244000	usd
CY2022Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1000000	usd
CY2021Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	750000	usd
CY2022Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1618000	usd
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	11735
CY2022	dei	City Area Code CityAreaCode	(212)
CY2022	dei	Local Phone Number LocalPhoneNumber	583-0100
CY2022	dei	Security12b Title Security12bTitle	Common Stock, $.01 par value
CY2022	dei	Trading Symbol TradingSymbol	ENZ
CY2022	dei	Security Exchange Name SecurityExchangeName	NYSE
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2021Q1	dei	Entity Public Float EntityPublicFloat	131825000	usd
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	48720454	shares
CY2022	dei	Auditor Firm AuditorFirmId	274
CY2022	dei	Auditor Name AuditorName	EisnerAmper LLP
CY2022	dei	Auditor Location AuditorLocation	New York, New York
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	21603000	usd
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	13524000	usd
CY2021Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	29978000	usd
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	11516000	usd
CY2021Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	10198000	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	15411000	usd
CY2021Q3	us-gaap	Inventory Net InventoryNet	12652000	usd
CY2022Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	5824000	usd
CY2021Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	4230000	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	54354000	usd
CY2021Q3	us-gaap	Assets Current AssetsCurrent	70582000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	17259000	usd
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	16585000	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	15174000	usd
CY2021Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	17020000	usd
CY2022Q3	us-gaap	Goodwill Goodwill	7452000	usd
CY2021Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1808000	usd
CY2022Q3	us-gaap	Assets Assets	95857000	usd
CY2021Q3	us-gaap	Assets Assets	113691000	usd
CY2022Q3	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	8508000	usd
CY2021Q3	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	8123000	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	12300000	usd
CY2021Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	14301000	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3432000	usd
CY2021Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3419000	usd
CY2022Q3	us-gaap	Other Short Term Borrowings OtherShortTermBorrowings	310000	usd
CY2021Q3	us-gaap	Other Short Term Borrowings OtherShortTermBorrowings	233000	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	24550000	usd
CY2021Q3	us-gaap	Liabilities Current LiabilitiesCurrent	26076000	usd
CY2022Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	39000	usd
CY2021Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	115000	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	12729000	usd
CY2021Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	14558000	usd
CY2022Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	4077000	usd
CY2021Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	4356000	usd
CY2022Q3	us-gaap	Liabilities Liabilities	41395000	usd
CY2021Q3	us-gaap	Liabilities Liabilities	45105000	usd
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2021Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2021Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	48720454	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	48720454	shares
CY2021Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	48471771	shares
CY2021Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	48471771	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	487000	usd
CY2021Q3	us-gaap	Common Stock Value CommonStockValue	485000	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	339462000	usd
CY2021Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	337126000	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-288638000	usd
CY2021Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-270377000	usd
CY2022Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	3151000	usd
CY2021Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1352000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	54462000	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	68586000	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	95857000	usd
CY2021Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	113691000	usd
CY2022	us-gaap	Revenues Revenues	107071000	usd
CY2021	us-gaap	Revenues Revenues	117731000	usd
CY2020	us-gaap	Revenues Revenues	76021000	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	65104000	usd
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	64154000	usd
CY2020	us-gaap	Cost Of Revenue CostOfRevenue	52251000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3767000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3252000	usd
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4448000	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	48018000	usd
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	44905000	usd
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	42960000	usd
CY2022	us-gaap	Legal Fees LegalFees	5689000	usd
CY2021	us-gaap	Legal Fees LegalFees	4728000	usd
CY2020	us-gaap	Legal Fees LegalFees	6729000	usd
CY2022	us-gaap	Payments For Legal Settlements PaymentsForLegalSettlements	500000	usd
CY2022	enz	Total Costs Expenses And Legal Settlements Net TotalCostsExpensesAndLegalSettlementsNet	122078000	usd
CY2021	enz	Total Costs Expenses And Legal Settlements Net TotalCostsExpensesAndLegalSettlementsNet	117039000	usd
CY2020	enz	Total Costs Expenses And Legal Settlements Net TotalCostsExpensesAndLegalSettlementsNet	106388000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-15007000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	692000	usd
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-30367000	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	159000	usd
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	8000	usd
CY2020	us-gaap	Investment Income Interest InvestmentIncomeInterest	454000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1191000	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	6905000	usd
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	488000	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-2222000	usd
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	270000	usd
CY2020	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	905000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-18261000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	7875000	usd
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-28520000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-18261000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	7875000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-28520000	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.38
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.16
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.6
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.38
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.16
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.6
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	48594	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	48191	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	47696	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	48594	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	48325	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	47696	shares
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-18261000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	7875000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-28520000	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	1799000	usd
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-329000	usd
CY2020	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-899000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-16462000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	7546000	usd
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-29419000	usd
CY2019Q3	us-gaap	Stockholders Equity StockholdersEquity	86028000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-28520000	usd
CY2020	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	10000	usd
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	923000	usd
CY2020	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	839000	usd
CY2020	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-899000	usd
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	58381000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	7875000	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	97000	usd
CY2021	enz	Stock Issued During Period Issuance Of Common Stock For Bonus Payments StockIssuedDuringPeriodIssuanceOfCommonStockForBonusPayments	875000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	907000	usd
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	780000	usd
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-329000	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	68586000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-18261000	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	28000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1496000	usd
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	814000	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	1799000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	54462000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-18261000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	7875000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-28520000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2566000	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2332000	usd
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2256000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	261000	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	321000	usd
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	524000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1496000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	907000	usd
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	933000	usd
CY2022	enz	Sharebased401k Employer Match Expense Sharebased401kEmployerMatchExpense	843000	usd
CY2020	us-gaap	Amount Of Dilutive Securities Stock Options And Restrictive Stock Units AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits		usd
CY2021	enz	Sharebased401k Employer Match Expense Sharebased401kEmployerMatchExpense	731000	usd
CY2020	enz	Sharebased401k Employer Match Expense Sharebased401kEmployerMatchExpense	836000	usd
CY2022	enz	Foreign Currency Gain Loss On Intercompany Loan ForeignCurrencyGainLossOnIntercompanyLoan	-2057000	usd
CY2021	enz	Foreign Currency Gain Loss On Intercompany Loan ForeignCurrencyGainLossOnIntercompanyLoan	88000	usd
CY2020	enz	Foreign Currency Gain Loss On Intercompany Loan ForeignCurrencyGainLossOnIntercompanyLoan	1165000	usd
CY2022	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-1283000	usd
CY2021	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-83000	usd
CY2021	us-gaap	Payments Of Loan Costs PaymentsOfLoanCosts	7000000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1299000	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1110000	usd
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1617000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2736000	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	4937000	usd
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-85000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1174000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	707000	usd
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	216000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	390000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-395000	usd
CY2020	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	1214000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-2016000	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	2375000	usd
CY2020	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	5257000	usd
CY2022	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	1671000	usd
CY2021	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	-7488000	usd
CY2020	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	11341000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16590000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	387000	usd
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-17179000	usd
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	3472000	usd
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	4436000	usd
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	2170000	usd
CY2022	enz	Salespurchases Of Marketable Securities SalespurchasesOfMarketableSecurities	-28695000	usd
CY2021	enz	Salespurchases Of Marketable Securities SalespurchasesOfMarketableSecurities	30061000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	25223000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-34497000	usd
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2170000	usd
CY2020	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	7412000	usd
CY2022	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	269000	usd
CY2021	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	339000	usd
CY2022	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit		usd
CY2020	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	411000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	28000	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	97000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-241000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-242000	usd
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7001000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-63000	usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	11000	usd
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	67000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	8329000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-34341000	usd
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-12281000	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	14274000	usd
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	48615000	usd
CY2019Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	60896000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	22603000	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	14274000	usd
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	48615000	usd
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	21603000	usd
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	13524000	usd
CY2020Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	47865000	usd
CY2022Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1000000	usd
CY2021Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	750000	usd
CY2020Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	750000	usd
CY2022Q3	enz	Cash Cash Equivalentsand Restricted Cash CashCashEquivalentsandRestrictedCash	22603000	usd
CY2021Q3	enz	Cash Cash Equivalentsand Restricted Cash CashCashEquivalentsandRestrictedCash	14274000	usd
CY2020Q3	enz	Cash Cash Equivalentsand Restricted Cash CashCashEquivalentsandRestrictedCash	48615000	usd
CY2022	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	3	pure
CY2022Q3	us-gaap	Retained Earnings Appropriated RetainedEarningsAppropriated	288261000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-18261000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16590000	usd
CY2022	us-gaap	Advertising Expense AdvertisingExpense	577000	usd
CY2021	us-gaap	Advertising Expense AdvertisingExpense	400000	usd
CY2021	enz	Amortization Expense Gross AmortizationExpenseGross		usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Use of Estimates</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
CY2021Q3	us-gaap	Marketable Securities MarketableSecurities	29978000	usd
CY2021Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	30061000	usd
CY2021	us-gaap	Unrealized Loss On Securities UnrealizedLossOnSecurities	83000	usd
CY2022	us-gaap	Debt Securities Trading Realized Loss DebtSecuritiesTradingRealizedLoss	1283000	usd
CY2020	us-gaap	Advertising Expense AdvertisingExpense	437000	usd
CY2021Q3	us-gaap	Inventory Net InventoryNet	12652000	usd
CY2022Q3	enz	Deferred Tax Assets Lease Liabilities DeferredTaxAssetsLeaseLiabilities	4594000	usd
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Concentration of Credit Risk</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash and cash equivalents and accounts receivable. The Company believes the fair value of the aforementioned financial instruments approximates the cost due to the immediate or short-term nature of these items.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Concentration of credit risk with respect to the Company’s Life Sciences products segment is mitigated by the diversity of the Company’s customers and their dispersion across many different geographic regions. To reduce risk, the Company routinely assesses the financial strength of these customers and, consequently, believes that its accounts receivable credit exposure with respect to these customers is limited.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company believes that the concentration of credit risk with respect to the Clinical Laboratory services accounts receivable is mitigated by the diversity of third party payers that insure individuals. To reduce risk, the Company routinely assesses the financial strength of these payers and, consequently, believes that its accounts receivable credit risk exposure, with respect to these payers, is limited. While the Company also has receivables due from the Federal Medicare program, the Company does not believe that these receivables represent a credit risk since the Medicare program is funded by the federal government and payment is primarily dependent on our submitting the appropriate documentation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Other than the Medicare program, two providers whose programs are included in the “Third party payers” and health maintenance organizations (“HMOs”) categories represent 21%, 22% and 24%, respectively, of Clinical Services net revenue for the years ended July 31, 2022, 2021 and 2020 respectively, and represent 23% and 27% respectively, of the Clinical Services net accounts receivable as of July 31, 2022 and 2021. Other than the Medicare program, one provider whose programs are included in the “Third-party payers” and “Health Maintenance Organizations” (“HMO’s”) categories represents 11% and 13%, respectively, of Clinical Services net revenues for the years ended July 31, 2022 and 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	933000	usd
CY2022	enz	Accrual For Self Funded Medical Policytextblock AccrualForSelfFundedMedicalPolicytextblock	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Accrual for Self-Funded Employee Medical Insurance</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Accruals for self-funded employee medical insurance are determined based on a number of assumptions and factors, including historical payment trends, claims history and current estimates. These estimated liabilities are not discounted as they are expected to be repaid within one year. If actual trends differ from these estimates, the financial results could be impacted.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
CY2022	enz	Contractual Adjustment Percentage ContractualAdjustmentPercentage	0.83	pure
CY2021	enz	Contractual Adjustment Percentage ContractualAdjustmentPercentage	0.83	pure
CY2020	enz	Contractual Adjustment Percentage ContractualAdjustmentPercentage	0.88	pure
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	11516000	usd
CY2021Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	10198000	usd
CY2020Q3	us-gaap	Accounts Receivable Related Parties AccountsReceivableRelatedParties	6180000	usd
CY2020	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	10000	usd
CY2022	us-gaap	Variable Interest Entity Activity Between Vie And Entity Income Or Loss Before Tax VariableInterestEntityActivityBetweenVIEAndEntityIncomeOrLossBeforeTax	839000	usd
CY2022Q3	us-gaap	Variable Interest Difference Between Carrying Amount And Maximum Exposure VariableInterestDifferenceBetweenCarryingAmountAndMaximumExposure	55000000	usd
CY2022	enz	Shipping And Handling Costs Policy Tet Block ShippingAndHandlingCostsPolicyTetBlock	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Shipping and Handling Costs</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Shipping and handling costs associated with the distribution of finished goods to customers are recorded in cost of goods sold.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
CY2021	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	134000	shares
CY2022	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	472000	shares
CY2022	us-gaap	Net Income Loss Allocated To Limited Partners NetIncomeLossAllocatedToLimitedPartners	-18261000	usd
CY2021	us-gaap	Net Income Loss Allocated To Limited Partners NetIncomeLossAllocatedToLimitedPartners	7875000	usd
CY2020	us-gaap	Net Income Loss Allocated To Limited Partners NetIncomeLossAllocatedToLimitedPartners	-28520000	usd
CY2022	enz	Weightedaverage Common Share Outstanding Basic WeightedaverageCommonShareOutstandingBasic	48594	shares
CY2021	enz	Weightedaverage Common Share Outstanding Basic WeightedaverageCommonShareOutstandingBasic	48191	shares
CY2020	enz	Weightedaverage Common Share Outstanding Basic WeightedaverageCommonShareOutstandingBasic	47696	shares
CY2021	us-gaap	Amount Of Dilutive Securities Stock Options And Restrictive Stock Units AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits	134000	usd
CY2022	enz	Weightedaverage Common Share Outstanding Diluted WeightedaverageCommonShareOutstandingDiluted	48594	shares
CY2021	enz	Weightedaverage Common Share Outstanding Diluted WeightedaverageCommonShareOutstandingDiluted	48325	shares
CY2020	enz	Weightedaverage Common Share Outstanding Diluted WeightedaverageCommonShareOutstandingDiluted	47696	shares
CY2022	enz	Earning Per Share Basic EarningPerShareBasic	-0.38	shares
CY2021	enz	Earning Per Share Basic EarningPerShareBasic	0.16	shares
CY2020	enz	Earning Per Share Basic EarningPerShareBasic	-0.6	shares
CY2022	enz	Earning Per Share Basic And Diluted EarningPerShareBasicAndDiluted	-0.38	shares
CY2021	enz	Earning Per Share Basic And Diluted EarningPerShareBasicAndDiluted	0.16	shares
CY2020	enz	Earning Per Share Basic And Diluted EarningPerShareBasicAndDiluted	-0.6	shares
CY2022Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	1524000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	1496000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	907000	usd
CY2022	enz	Share Based Compensations ShareBasedCompensations	1496000	usd
CY2021	enz	Share Based Compensations ShareBasedCompensations	907000	usd
CY2020	enz	Share Based Compensations ShareBasedCompensations	933000	usd
CY2022	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Reclassification</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Certain prior period amounts have been reclassified to conform to the current period presentation. These reclassifications had no effect on the reported results of operations.</p>
CY2022Q3	us-gaap	Goodwill Goodwill	7452000	usd
CY2021Q3	us-gaap	Goodwill Goodwill	7452000	usd
CY2021Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	1062000	usd
CY2022Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	2459000	usd
CY2020Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	27686000	usd
CY2020Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-27148000	usd
CY2020Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	538000	usd
CY2021	enz	Amortization Expenses Accumulated Amortization AmortizationExpensesAccumulatedAmortization	296000	usd
CY2021Q3	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	296000	usd
CY2021	enz	Finite Lived Intangible Assets Translation Adjustments Gross FiniteLivedIntangibleAssetsTranslationAdjustmentsGross	89000	usd
CY2021	enz	Finite Lived Intangible Assets Amortization Of Translation Adjustments FiniteLivedIntangibleAssetsAmortizationOfTranslationAdjustments	87000	usd
CY2021	us-gaap	Finite Lived Intangible Assets Foreign Currency Translation Gain Loss FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss	2000	usd
CY2021Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	27775000	usd
CY2021Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-27531000	usd
CY2021Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	244000	usd
CY2022	enz	Amortization Expenses Accumulated Amortization AmortizationExpensesAccumulatedAmortization	239000	usd
CY2022Q3	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	239000	usd
CY2022	enz	Finite Lived Intangible Assets Translation Adjustments Gross FiniteLivedIntangibleAssetsTranslationAdjustmentsGross	-512000	usd
CY2022	enz	Finite Lived Intangible Assets Amortization Of Translation Adjustments FiniteLivedIntangibleAssetsAmortizationOfTranslationAdjustments	-507000	usd
CY2022	us-gaap	Finite Lived Intangible Assets Foreign Currency Translation Gain Loss FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss	-5000	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	27263000	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-27263000	usd
CY2022Q3	us-gaap	Other Finite Lived Intangible Assets Gross OtherFiniteLivedIntangibleAssetsGross	27263000	usd
CY2022Q3	enz	Finitelived Intangible Assets Accumulated Amortization FinitelivedIntangibleAssetsAccumulatedAmortization	-27263000	usd
CY2021Q3	us-gaap	Other Finite Lived Intangible Assets Gross OtherFiniteLivedIntangibleAssetsGross	27775000	usd
CY2021Q3	enz	Finitelived Intangible Assets Accumulated Amortization FinitelivedIntangibleAssetsAccumulatedAmortization	-27531000	usd
CY2021Q3	enz	Finitelived Intangible Asset Net FinitelivedIntangibleAssetNet	244000	usd
CY2022	enz	Amortization Expense AmortizationExpense	239000	usd
CY2021	enz	Amortization Expense AmortizationExpense	296000	usd
CY2020	enz	Amortization Expense AmortizationExpense	524000	usd
CY2021Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	2534000	usd
CY2022Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	11428000	usd
CY2021Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	9056000	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	15411000	usd
CY2020Q2	enz	Income Grants IncomeGrants	1496000	usd
CY2020Q2	enz	Income Grants IncomeGrants	1496000	usd
CY2021Q3	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	850000	usd
CY2022Q3	enz	Research And Development And Other Tax Credit Carryforwards ResearchAndDevelopmentAndOtherTaxCreditCarryforwards	1551000	usd
CY2021Q3	enz	Research And Development And Other Tax Credit Carryforwards ResearchAndDevelopmentAndOtherTaxCreditCarryforwards	1527000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	231000	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	237000	usd
CY2020	us-gaap	Interest Paid Net InterestPaidNet	266000	usd
CY2022	enz	Non Cash Right Of Use Assets And Lease Liabilities NonCashRightOfUseAssetsAndLeaseLiabilities	29000	usd
CY2021	enz	Non Cash Right Of Use Assets And Lease Liabilities NonCashRightOfUseAssetsAndLeaseLiabilities	74000	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	129000	usd
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	305000	usd
CY2020	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	90000	usd
CY2022	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	814000	usd
CY2021	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	780000	usd
CY2020	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	839000	usd
CY2021	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	332700	shares
CY2021Q3	us-gaap	Accrued Bonuses Current And Noncurrent AccruedBonusesCurrentAndNoncurrent	875000	usd
CY2021Q3	enz	Deferred Tax Assets Lease Liabilities DeferredTaxAssetsLeaseLiabilities	5194000	usd
CY2022Q3	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Foreign DeferredTaxAssetsTaxCreditCarryforwardsForeign	3213000	usd
CY2021Q3	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Foreign DeferredTaxAssetsTaxCreditCarryforwardsForeign	2536000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	46636000	usd
CY2021Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	44665000	usd
CY2022Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	31439000	usd
CY2021Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	30142000	usd
CY2022Q3	enz	Property Plant And Equipment Gross Excluding Land And Land Improvements PropertyPlantAndEquipmentGrossExcludingLandAndLandImprovements	15197000	usd
CY2021Q3	enz	Property Plant And Equipment Gross Excluding Land And Land Improvements PropertyPlantAndEquipmentGrossExcludingLandAndLandImprovements	14523000	usd
CY2022Q3	us-gaap	Land And Land Improvements LandAndLandImprovements	2062000	usd
CY2021Q3	us-gaap	Land And Land Improvements LandAndLandImprovements	2062000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	17259000	usd
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	16585000	usd
CY2022Q3	us-gaap	Investment Building And Building Improvements InvestmentBuildingAndBuildingImprovements	323000	usd
CY2022Q3	enz	Federal Tax Carryforward Losses FederalTaxCarryforwardLosses	20303000	usd
CY2021Q3	enz	Federal Tax Carryforward Losses FederalTaxCarryforwardLosses	18140000	usd
CY2022Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	635000	usd
CY2021Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	970000	usd
CY2022Q3	enz	State And Local Tax Carry Forward Losses StateAndLocalTaxCarryForwardLosses	2758000	usd
CY2021Q3	enz	State And Local Tax Carry Forward Losses StateAndLocalTaxCarryForwardLosses	1658000	usd
CY2021	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit		usd
CY2022Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1766000	usd
CY2021Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1088000	usd
CY2022Q3	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	875000	usd
CY2022	enz	Amortization Expense Gross AmortizationExpenseGross		usd
CY2022Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet	481000	usd
CY2021Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet	858000	usd
CY2022Q3	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	1769000	usd
CY2021Q3	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	1637000	usd
CY2022Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	2199000	usd
CY2021Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	1341000	usd
CY2022Q3	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	12000	usd
CY2021Q3	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	17000	usd
CY2022Q3	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	40156000	usd
CY2021Q3	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	35816000	usd
CY2022Q3	enz	Right Of Use Assets RightOfUseAssets	4313000	usd
CY2021Q3	enz	Right Of Use Assets RightOfUseAssets	4917000	usd
CY2022Q3	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	1175000	usd
CY2021Q3	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	946000	usd
CY2022Q3	enz	Deferred Tax Liabilities Other Net DeferredTaxLiabilitiesOtherNet	-58000	usd
CY2021Q3	enz	Deferred Tax Liabilities Other Net DeferredTaxLiabilitiesOtherNet	-79000	usd
CY2022Q3	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	5546000	usd
CY2021Q3	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	5942000	usd
CY2022Q3	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	34610000	usd
CY2021Q3	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	29874000	usd
CY2022Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	34610000	usd
CY2021Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	29874000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	4736000	usd
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-203000	usd
CY2022	us-gaap	Operating Loss Carryforwards Limitations On Use OperatingLossCarryforwardsLimitationsOnUse	the Company had U.S. federal net operating loss carryforwards of approximately $96,679 of which $58,867, if not fully utilized, expire between 2030 and 2038 and which $37,812 do not expire.
CY2022	us-gaap	Income Tax Examination Description IncomeTaxExaminationDescription	Utilization is dependent on generating sufficient taxable income prior to expiration of the tax loss carryforwards. In addition, the Company has research and development tax credit carryforwards of approximately $1,551 which expire between 2025 and 2042. As of July 31, 2022, the Company has state and local net operating loss carryforwards of approximately $38,133, which if not fully utilized, expire between 2038 and 2042.
CY2022Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Not Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration	14831000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-18261000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	7875000	usd
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-28520000	usd
CY2022Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	230000	usd
CY2022Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	237000	usd
CY2022Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	247000	usd
CY2022	enz	Effective Income Tax Rate Reconciliations At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationsAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2021	enz	Effective Income Tax Rate Reconciliations At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationsAtFederalStatutoryIncomeTaxRate	-0.21	pure
CY2020	enz	Effective Income Tax Rate Reconciliations At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationsAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.029	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.034	pure
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.011	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.187	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.181	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.057	pure
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.199	pure
CY2018Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	4500000	usd
CY2018Q4	enz	Debt Instrument Maturity Period DebtInstrumentMaturityPeriod	10 years
CY2018Q4	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.0509	pure
CY2018Q4	us-gaap	Debt Instrument Periodic Payment DebtInstrumentPeriodicPayment	30000	usd
CY2018Q4	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	72000	usd
CY2022Q3	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	46000	usd
CY2022Q3	us-gaap	Due To Affiliate Current And Noncurrent DueToAffiliateCurrentAndNoncurrent	3980000	usd
CY2022Q3	us-gaap	Cash Collateral For Borrowed Securities CashCollateralForBorrowedSecurities	1000000	usd
CY2022	us-gaap	Lessee Operating Lease Description LesseeOperatingLeaseDescription	We assumed from the seller an operating lease for a tenant at the facility which expired on June 30, 2020.
CY2022Q3	enz	Liquid Assets LiquidAssets	25000000	usd
CY2021Q3	enz	Description Of Loan DescriptionOfLoan	Effective September 29, 2021, the Company and the mortgagee agreed to further covenant restructuring whereby (a) the liquidity covenant was reduced to 150% of the loan principal (or approximately $6,000 as of July 31, 2022) from $25,000 previously, and (b) the collateral requirement was increased from $750 to $1,000.
CY2020Q2	enz	Foreign Exchange Rate Amount ForeignExchangeRateAmount	400000	chf
CY2020Q3	enz	Foreign Exchange Rate Amount ForeignExchangeRateAmount	400000	usd
CY2022Q3	us-gaap	Derivative Fixed Interest Rate DerivativeFixedInterestRate	0	pure
CY2022Q1	enz	Semiannual Amortization Payments SemiannualAmortizationPayments	33000	chf
CY2022Q1	enz	Exchange Rates ExchangeRates	33000	chf
CY2022Q1	enz	Exchange Rates ExchangeRates	35000	usd
CY2022	enz	Fixed Interest Rate Description FixedInterestRateDescription	PPP loans have a 1% fixed interest rate and are due from two to five years.
CY2021	enz	Other Income Loan OtherIncomeLoan	7000000	usd
CY2022	enz	Audit Loans AuditLoans	2000000	usd
CY2022Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	256000	usd
CY2022Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	266000	usd
CY2022Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive	3116000	usd
CY2022Q3	us-gaap	Long Term Debt LongTermDebt	4352000	usd
CY2022Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	229000	usd
CY2022Q3	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	46000	usd
CY2022Q3	us-gaap	Other Long Term Debt Noncurrent OtherLongTermDebtNoncurrent	4077000	usd
CY2022	enz	Lease Option Maximum Extension Period LeaseOptionMaximumExtensionPeriod	P5Y
CY2022Q3	enz	Operating Rightofuse Assets OperatingRightofuseAssets	15174000	usd
CY2021Q3	enz	Operating Rightofuse Assets OperatingRightofuseAssets	17020000	usd
CY2022Q3	enz	Lease Rightof Use Asset LeaseRightofUseAsset	15346000	usd
CY2021Q3	enz	Lease Rightof Use Asset LeaseRightofUseAsset	17268000	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3432000	usd
CY2021Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3419000	usd
CY2022Q3	enz	Finance Leases Liability Current FinanceLeasesLiabilityCurrent	81000	usd
CY2021Q3	enz	Finance Leases Liability Current FinanceLeasesLiabilityCurrent	88000	usd
CY2022Q3	enz	Operating Operating Lease Liabilities Noncurrent OperatingOperatingLeaseLiabilitiesNoncurrent	12729000	usd
CY2021Q3	enz	Operating Operating Lease Liabilities Noncurrent OperatingOperatingLeaseLiabilitiesNoncurrent	14558000	usd
CY2022Q3	enz	Finance Leases Liability Noncurrent FinanceLeasesLiabilityNoncurrent	39000	usd
CY2021Q3	enz	Finance Leases Liability Noncurrent FinanceLeasesLiabilityNoncurrent	110000	usd
CY2022Q3	enz	Lease Liability LeaseLiability	16281000	usd
CY2021Q3	enz	Lease Liability LeaseLiability	18175000	usd
CY2022Q3	us-gaap	Finance Lease Right Of Use Asset Accumulated Amortization FinanceLeaseRightOfUseAssetAccumulatedAmortization	210000	usd
CY2021Q3	us-gaap	Finance Lease Right Of Use Asset Accumulated Amortization FinanceLeaseRightOfUseAssetAccumulatedAmortization	1100000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	4431000	usd
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	5474000	usd
CY2022	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	76000	usd
CY2021	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	137000	usd
CY2022	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	10000	usd
CY2021	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	16000	usd
CY2022	us-gaap	Lease Cost LeaseCost	4517000	usd
CY2021	us-gaap	Lease Cost LeaseCost	5627000	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet		usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	4129000	usd
CY2022Q3	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	81000	usd
CY2022Q3	us-gaap	Contractual Obligation Due In Next Twelve Months ContractualObligationDueInNextTwelveMonths	4210000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	3836000	usd
CY2022Q3	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	44000	usd
CY2022Q3	us-gaap	Contractual Obligation Due In Second Year ContractualObligationDueInSecondYear	3880000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	3503000	usd
CY2022Q3	us-gaap	Contractual Obligation Due In Third Year ContractualObligationDueInThirdYear	3503000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	3351000	usd
CY2022Q3	us-gaap	Contractual Obligation Due In Fourth Year ContractualObligationDueInFourthYear	3351000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	2507000	usd
CY2022Q3	us-gaap	Contractual Obligation Due In Fifth Year ContractualObligationDueInFifthYear	2507000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	808000	usd
CY2022Q3	us-gaap	Contractual Obligation Due After Fifth Year ContractualObligationDueAfterFifthYear	808000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	18134000	usd
CY2022Q3	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	125000	usd
CY2022Q3	us-gaap	Contractual Obligation ContractualObligation	18259000	usd
CY2022Q3	enz	Present Value Of Lease Liabilities Operating Leases PresentValueOfLeaseLiabilitiesOperatingLeases	16161000	usd
CY2022Q3	enz	Finance Leases Liability FinanceLeasesLiability	120000	usd
CY2022Q3	enz	Contractual Obligation Liability ContractualObligationLiability	16281000	usd
CY2022	enz	Lease Term And Discount Rate LeaseTermAndDiscountRate	<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Lease term and discount rate</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">Weighted-average remaining lease term (years):</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 9pt">Operating leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7 years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.6 years</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-left: 9pt">Finance leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.5 years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.5 years</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Weighted-average discount rate:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; padding-left: 9pt">Operating leases</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">5.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">4.9</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-left: 9pt">Finance leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.5</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7.4</td><td style="text-align: left">%</td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p>
CY2022Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y8M12D
CY2021Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y7M6D
CY2022Q3	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P1Y6M
CY2021Q3	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P2Y6M
CY2022Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.05	pure
CY2021Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.049	pure
CY2022Q3	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.045	pure
CY2021Q3	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.074	pure
CY2021Q3	enz	Current Portions Of Mortgage Loan CurrentPortionsOfMortgageLoan	152000	usd
CY2022Q3	enz	Current Portion Of Swiss CurrentPortionOfSwiss	70000	usd
CY2022Q3	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	4912000	usd
CY2021Q3	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	5856000	usd
CY2022Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	801000	usd
CY2021Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	628000	usd
CY2022Q3	enz	Accrued Legal Liabilities Current AccruedLegalLiabilitiesCurrent	4523000	usd
CY2021Q3	enz	Accrued Legal Liabilities Current AccruedLegalLiabilitiesCurrent	2554000	usd
CY2021Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	2675000	usd
CY2022Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2064000	usd
CY2021Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2588000	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	12300000	usd
CY2021Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	14301000	usd
CY2020Q2	us-gaap	Payments For Advance To Affiliate PaymentsForAdvanceToAffiliate	2526000	usd
CY2021	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	1847000	usd
CY2020	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	2526000	usd
CY2022Q3	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	260000	usd
CY2021Q3	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	300000	usd
CY2022	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	81000	usd
CY2021	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	81000	usd
CY2022Q3	enz	Current Portions Of Mortgage Loan CurrentPortionsOfMortgageLoan	159000	usd
CY2022Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	310000	usd
CY2021Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	233000	usd
CY2021Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021	enz	Percentage Of Commission Payable On Equity Offering PercentageOfCommissionPayableOnEquityOffering	0.03	pure
CY2021Q3	enz	Maximum Offering Price Under Sales Agreement MaximumOfferingPriceUnderSalesAgreement	20000000	usd
CY2014Q4	enz	Maximum Offering Price Under Sales Agreement MaximumOfferingPriceUnderSalesAgreement	20000000	usd
CY2022	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	237383	shares
CY2022	enz	Conversion Of Stock Amount Issued ConversionOfStockAmountIssued	814000	usd
CY2021	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	208537	shares
CY2021	enz	Conversion Of Stock Amount Issued ConversionOfStockAmountIssued	780000	usd
CY2021Q1	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	332700	shares
CY2021Q1	enz	Conversion Of Stock Amount Issued ConversionOfStockAmountIssued	875000	usd
CY2020	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	333265	shares
CY2020	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	839000	usd
CY2020Q3	us-gaap	Common Stock Shares Held In Employee Trust Shares CommonStockSharesHeldInEmployeeTrustShares	4167	shares
CY2020Q3	us-gaap	Common Stock Shares Held In Employee Trust CommonStockSharesHeldInEmployeeTrust	10000	usd
CY2020Q4	enz	Common Stock Available For Grant Description CommonStockAvailableForGrantDescription	The amendment and restatement of the Amended and Restated 2011 Plan was for purposes of, among other things, (i) increasing the shares of common stock available for grant under the Amended and Restated 2011 Plan by an additional 4,000,000 shares of common stock bringing the total number of shares available for grant to 9,000,000 shares of common stock and (ii) extending the term of the Amended and Restated 2011 Plan until October 7, 2030.
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	4142000	shares
CY2021Q4	enz	Purchase Of Common Stock PurchaseOfCommonStock	700000	shares
CY2021Q4	us-gaap	Restricted Stock Shares Issued Net Of Shares For Tax Withholdings RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings	260000	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2504563	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.74
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2636496	shares
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.05
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2351040	shares
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.53
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1858250	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.88
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	543104	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.57
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	773032	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.4
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	11300	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.49
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	34667	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.8
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	409730	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	7
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	640370	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	3.52
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	487576	shares
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	3.71
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3941783	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2504563	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.74
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2636496	shares
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.05
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1794399	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	3.14
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1561326	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4.37
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1457162	shares
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	5.1
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.52
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.27
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.01
CY2022Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding	68000	usd
CY2021Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding	488000	usd
CY2020Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding	0	usd
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	193000	usd
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	1323000	usd
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	79000	usd
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	4000	usd
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	38000	usd
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	0	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1858250	shares
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P5Y
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P3Y
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P3Y6M
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	543104	shares
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P5Y
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	773032	shares
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P5Y
CY2021	enz	Share Based Compensation Arrangement By Share Based Payment Award Options Expired Remaining Contractual Term1 ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredRemainingContractualTerm1	P3Y
CY2022	enz	Performance Shares Description PerformanceSharesDescription	During the fiscal years ended 2020 and 2019, the Company awarded additional PSUs to its executive officers. These awards provide for the grant of shares of our common stock at the end of a three–year period based on the achievement of revenue growth and adjusted EBITDA growth goals met at threshold, target or maximum levels over the respective period. For the fiscal year ended July 31, 2022, the Company reversed net total PSU accruals of $124 for a former officer who forfeited 25,300 and 20,000 PSUs from the fiscal 2020 and fiscal 2019 awards, respectively, resulting in net PSU compensation expense of $70. For the fiscal year ended July 31, 2021, the Company accrued compensation expense of $272 for the outstanding PSUs awarded during fiscal 2020 and 2019 as the achievement of certain growth goals was deemed probable at that time. During fiscal 2021, a former officer forfeited 4,000 PSUs awarded in fiscal 2019. During the fiscal year 2020, no compensation expense was recognized as the achievement of the growth goals was deemed not probable at that time. During fiscal 2020, a former executive forfeited 10,500 PSUs from the fiscal 2019 award.
CY2022	enz	Description Of Restricted Stock Units DescriptionOfRestrictedStockUnits	The Company awarded restricted stock units (“RSUs”) to our CEO who was appointed in November 2021. The award was for 260,000 RSUs which vest over three years on the anniversary of his hiring. The fair market value of these RSUs at the date of grant was $881. The Company awarded to its 3 independent directors 117,189 RSUs in April 2022 which vest over two years whose fair market value was $300. In July 2022 the Company awarded to its 3 independent directors 124,998 RSUs which vest in one year and whose fair market value was $300. During fiscal 2022, the Company recognized shared based compensation expense of $295 for these RSUs.
CY2022	enz	Unrecognized Compensation UnrecognizedCompensation	3835000	usd
CY2022	us-gaap	Net Amount At Risk By Product And Guarantee Weighted Average Period Remaining1 NetAmountAtRiskByProductAndGuaranteeWeightedAveragePeriodRemaining1	P2Y
CY2022	enz	Employees Contribution Percentage EmployeesContributionPercentage	0.50	pure
CY2021	enz	Employees Contribution Percentage EmployeesContributionPercentage	0.50	pure
CY2020	enz	Employees Contribution Percentage EmployeesContributionPercentage	0.50	pure
CY2022	enz	Employer Matched Contribution EmployerMatchedContribution	814000	usd
CY2021	enz	Employer Matched Contribution EmployerMatchedContribution	780000	usd
CY2020	enz	Employer Matched Contribution EmployerMatchedContribution	839000	usd
CY2022Q3	enz	Accrued Total AccruedTotal	462000	usd
CY2021Q3	enz	Accrued Total AccruedTotal	433000	usd
CY2020Q3	enz	Accrued Total AccruedTotal	481000	usd
CY2022	enz	Minimum Saving Contribution Description MinimumSavingContributionDescription	The current required minimum saving contribution is 13% for employees over age 25 and minimum annual investment return is 1.00%. Employees are required to contribute based on a formula and the Company’s Swiss operations make contributions of at least 40% of the employee contribution.
CY2022	us-gaap	Payments Of Loan Costs PaymentsOfLoanCosts		usd
CY2021Q3	enz	Total Asset TotalAsset	2667000	usd
CY2020Q3	enz	Total Asset TotalAsset	2721000	usd
CY2019Q3	enz	Total Asset TotalAsset	2181000	usd
CY2021Q3	us-gaap	Defined Benefit Plan Accumulated Benefit Obligation DefinedBenefitPlanAccumulatedBenefitObligation	2760000	usd
CY2020Q3	us-gaap	Defined Benefit Plan Accumulated Benefit Obligation DefinedBenefitPlanAccumulatedBenefitObligation	2890000	usd
CY2019Q3	us-gaap	Defined Benefit Plan Accumulated Benefit Obligation DefinedBenefitPlanAccumulatedBenefitObligation	2401000	usd
CY2021Q3	enz	Funded Status FundedStatus	0.97	pure
CY2020Q3	enz	Funded Status FundedStatus	0.94	pure
CY2019Q3	enz	Funded Status FundedStatus	0.91	pure
CY2021	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	144000	usd
CY2020	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	143000	usd
CY2019	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	165000	usd
CY2022Q3	enz	Annual Increases Percenatge AnnualIncreasesPercenatge	0.03	pure
CY2022	enz	Operating Leases Rent Expense OperatingLeasesRentExpense	1867000	usd
CY2021	enz	Operating Leases Rent Expense OperatingLeasesRentExpense	1815000	usd
CY2020	enz	Operating Leases Rent Expense OperatingLeasesRentExpense	1833000	usd
CY2022	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 15 – Contingencies</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company has brought cases in the United States District Court for the District of Delaware (“the Court”), alleging patent infringement against various companies. In 2017, the Court ruled that the asserted claims of the ’180 and ’405 Patents are invalid for nonenablement in cases involving Abbott, Becton Dickinson, Gen-Probe, Hologic, and Roche. That ruling was affirmed by the United States Court of Appeals for the Federal Circuit (“Federal Circuit”) in June 2019. Enzo subsequently filed a petition for certiorari regarding the invalidity ruling for the ’180 and ’405 Patents in February 2020; the Supreme Court denied Enzo’s petition on March 30, 2020.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company, along with its subsidiary Enzo Life Sciences, Inc., resolved its claims against Roche regarding the ‘197 Patent before the Court (civil action No. 12 cv-00106) in July 2022. There is currently one case that was originally brought by the Company that is still pending in the Court. In that case, Enzo alleges patent infringement of the ‘197 patent against Becton Dickinson Defendants. The claims in that case are stayed.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In separate inter partes review proceedings before the U.S. Patent and Trademark Office (PTO) involving, among others, Becton Dickinson, certain claims of the ’197 Patent were found unpatentable as anticipated or obvious and cancelled by the Patent Trial and Appeals Board (“Board”). Enzo appealed that decision to the Federal Circuit. On August 16, 2019, the Federal Circuit affirmed the Board’s decision, finding that each of the challenged claims is unpatentable. The Company filed a petition for rehearing and rehearing en banc on October 30, 2019, which the Federal Circuit denied on December 4, 2019. The Company filed a petition for certiorari with the Supreme Court on March 3, 2020, which was denied.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In April 2019, the Company entered into an agreement with Hologic and Grifols, resolving litigation resulting from four cases originally brought by the Company in the Court. As a result, Enzo dismissed (1) a stayed patent litigation regarding the ’180 and ’197 Patent against Hologic in the Court; (2) the Consolidated Appeals against Gen-Probe and Hologic resulting from two cases filed in the Court, and (3) the Company’s appeal in the litigation involving the ’581 Patent that involved both Hologic and Grifols. As a result of the agreement with Hologic, Hologic withdrew from Enzo’s Federal Circuit appeal of the Board’s adverse rulings in the <i>inter partes</i> review proceedings regarding the ’197 Patent filed by Hologic and joined by Becton Dickinson mentioned above.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On September 2, 2021, the PTO issued a non-final office action in an ex parte reexamination concerning the ’197 Patent. In the office action, the PTO rejected certain claims of the ’197 Patent under 35 U.S.C. § 102 and for nonstatutory double-patenting. Enzo responded to the office action on January 3, 2022. Beckton Dickinson filed another <i>ex parte</i> reexamination concerning the ‘197 patent on July 26, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On February 5, 2020, Harbert Discovery Fund, LP and Harbert Discovery Co-Investment Fund I, LP (“HDF”) brought an action in the United States District Court for the Southern District of New York against the Company and five of its present or former Directors, Dr. Elazar Rabbani, Barry W. Weiner, Dr. Bruce A. Hanna, Dov Perlysky and Rebecca Fischer. On March 26, 2020, HDF filed an amended complaint against the same defendants. Count I asserted the Company violated Section 14(a) of the Securities and Exchange Act of 1934 and Rule 14a-9 thereunder by disseminating proxy materials that made purportedly false statements. Count II asserted a claim against the individual defendants under Section 20(a) of the Exchange Act premised on Enzo’s purported violation of Section 14(a) and Rule 14a-9. Count III asserted the individual defendants breached their fiduciary duty, based on the same conduct and by seeking to entrench themselves. Finally, Count IV purported to assert a derivative claim for a declaration that any amendment to Article II, Section 2 requires the approval of 80% of Enzo’s shareholders. On July 16, 2020, the day before the defendants’ motion to dismiss was due, HDF asked the Court to dismiss their claims without prejudice. Defendants asked HDF to dismiss the claims with prejudice, but they refused. On July 17, 2020, the Court dismissed the claims without prejudice.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On November 27, 2020, the Company brought an action in the United States District Court for the Southern District of New York against Harbert Discovery Fund, LP, Harbert Discovery Co-Investment Fund I, LP, Harbert Fund Advisors, Inc., Harbert Management Corp. and Kenan Lucas (together, “Harbert”). The Company alleges Harbert made false and misleading representations, or omitted to state material facts necessary to make their statements not misleading, in proxy materials they disseminated seeking the election to the Company’s Board of Directors at its 2019 Annual Meeting of two candidates they nominated, in violation of Section 14(a) of the 1934 Exchange Act and Rule 14a-9 thereunder. The Company seeks damages and injunctive relief. On October 12, 2021, HDF filed nine counterclaims against the Company and present and former directors Dr. Elazar Rabbani, Barry W. Weiner, Dr. Bruce A. Hanna, Dov Perlysky, Rebeca Fischer, Dr. Mary Tagliaferri and Dr. Ian B. Walters. HDF claims the Company made false and misleading representations in proxy materials it disseminated in connection with its 2019 Annual Meeting, in violation of Section 14(a) of the 1934 Exchange Act and Rule 14a-9 thereunder, and that the Company’s directors at that time are liable under Section 20(a) of the Exchange Act for the Company’s purported misstatements. HDF also claims that current and former Company directors breached their fiduciary duties by taking four corporate actions: (a) adjourning the 2019 meeting for 25 days; (b) purportedly causing the two Harbert candidates for director, who were elected at the 2019 Meeting, to resign in November 2020; (c) authorizing the November 27, 2020 Lawsuit; and (d) not accepting Dr. Rabbani’s resignation as a director in March 2021. On November 10, 2021, the Company and the other counterclaim defendants moved to dismiss HDF’s counterclaims. On December 9, 2021, the court granted the motion to dismiss HDF’s counterclaims except HDF’s Section 14(a) claim against the Company concerning its statement that it intended to “delay” the 2019 Annual Meeting, and HDF’s Section 20(a) and breach of fiduciary duty counterclaims against Dr. Elazar Rabbani, Barry W. Weiner, Dr. Bruce Hanna, Dov Perlysky and Rebecca Fischer with respect to that statement. The Court allowed HDF to move for leave to replead with respect to its dismissed counterclaims. On June 7, 2022, the Court “so ordered” a stipulation of dismissal with prejudice of the Company’s claims against Harbert Discovery Fund, LP, Harbert Discovery Co-Investment Fund I, LP, Harbert Fund Advisors, Inc., Harbert Management Corp., and Kenan Lucas, and HDF’s counterclaims against the Company, Dr. Bruce Hanna, Dov Perlysky, Rebecca Fischer, Dr. Ian B. Walters and Dr. Mary Tagliaferri. The only remaining claims are HDF’s counterclaims against Dr. Rabbani and Mr. Weiner. HDF has asked the Court to dismiss those claims without prejudice. Dr. Rabbani and Mr. Weiner have asked the Court to dismiss those counterclaims with prejudice and to allow them to take discovery from HDF, the Company, and possibly others.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">There can be no assurance that the Company will be successful in any of these litigations. Even if the Company is not successful, management does not believe that there will be a significant adverse monetary impact on the Company. The Company is party to other claims, legal actions, complaints, and contractual disputes that arise in the ordinary course of business. The Company believes that any liability that may ultimately result from the resolution of these matters will not, individually or in the aggregate, have a material adverse effect on its financial position or results of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As described in Note 3, third-party payers, including government programs, may decide to deny payment or recoup payments for testing that they contend was improperly billed or not medically necessary, against their coverage determinations, or for which they believe they have otherwise overpaid (including as a result of their own error), and we may be required to refund payments already received. During the third fiscal quarter of 2019, a significant third-party payer informed us outside of their typical business practice that they believe it overpaid the Company during certain periods of fiscal 2018. The Company disputed these claims and formally sent legal appeal letters to the payer. During the fiscal 2020 period, we recorded $0.8 million in legal and related expenses as a result of reduced reimbursements this payer made to us. In April 2020, we and the payer entered into a settlement agreement and release whereby the parties agreed that the $0.8 million previously withheld by the payer shall fully and completely satisfy the dispute.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company, along with its subsidiary Enzo Life Sciences, Inc. entered into a Settlement Agreement as of July 26, 2022 (the “Agreement) with Roche Molecular Systems, Inc., et al. with respect to an action between the Company and Roche before the U.S. District Court, Southern District of New York, civil action No. 12 cv-00106. Roche agreed to pay the Company $0.5 million in settlement pursuant to the Agreement, which is included in Legal Settlements. The Company paid $0.15 million as an attorney contingency payment, which is included in Legal and related expenses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Former executives arbitration</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company terminated the employment of Elazar Rabbani, Ph.D. the Company’s former Chief Executive Officer, effective April 21, 2022. Dr. Rabbani remains a board director of the Company. Dr. Rabbani is a party to an employment agreement with the Company, which entitles him to certain termination benefits, including severance pay, acceleration of vesting of share-based compensation, continuation of benefits and tax gross up certain of these termination benefits. Based on the terms of his employment agreement, the Company estimated and accrued a charge of $2,600 in fiscal 2022 which is included in Selling, general and administrative expenses. The charge was partially offset by the reversal of bonus accruals. In May 2022, the Company paid Dr. Rabbani $2,123 in accordance with terms of the employment contract. In July 2022, the Company paid income and other withholding taxes of $1,024 related to that payment on Dr. Rabbani’s behalf, which is included in “prepaid expense and other current assets” as of July 31, 2022, as the payment is reimbursable from Dr. Rabbani. Dr. Rabbani disputed the Company’s decision to not award him a bonus for fiscal year 2021 and the amount of severance that was owed to him under his employment agreement. On July 8, 2022, the Company filed a demand for arbitration with the American Arbitration Association (the “AAA”) seeking, among other things, a declaration that the Company has fully satisfied its contractual obligations to Dr. Rabbani. On August 4, 2022, Dr. Rabbani filed counterclaims in the arbitration seeking, among other things, a bonus for fiscal year 2021 and additional severance that he asserts is owed to him. The parties have chosen an arbitrator from the AAA’s panel and a hearing is scheduled for June 8-16, 2023.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On February 25, 2022, Barry Weiner, the Company’s co-founder and President, notified the Company that he was terminating his employment as President of the Company for “Good Reason” as defined in his employment agreement. The Company accepted Mr. Weiner’s termination, effective April 19, 2022 but disagrees with Mr. Weiner’s assertion regarding “Good Reason.” On July 20, 2022, Barry Weiner, the Company’s former Chief Financial Officer, filed a demand for arbitration with the AAA asserting, among other things, that his annual bonus for fiscal year 2021 was too low and that his resignation (effective April 19, 2022) was for “Good Reason” under the terms of his employment agreement. He seeks, among other things, payment of a higher 2021 bonus, and severance payments and benefits. An arbitrator has not yet been selected from the AAA’s panel. As of July 31, 2022, the Company has not accrued any charges related to Mr. Weiner’s termination.</p>
CY2022	enz	Approval Percentage ApprovalPercentage	0.80	pure
CY2020	us-gaap	Other Expenses OtherExpenses	800000	usd
CY2020Q2	us-gaap	Litigation Settlement Amount Awarded From Other Party LitigationSettlementAmountAwardedFromOtherParty	800000	usd
CY2022	us-gaap	Payments For Legal Settlements PaymentsForLegalSettlements	500000	usd
CY2022	us-gaap	Loss Contingency Accrual Payments LossContingencyAccrualPayments	150000	usd
CY2022	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	2600000	usd
CY2022Q2	us-gaap	Proceeds From Legal Settlements ProceedsFromLegalSettlements	2123000	usd
CY2022Q3	us-gaap	Payments For Other Taxes PaymentsForOtherTaxes	1024000	usd
CY2022	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	3	pure
CY2020	us-gaap	Payments Of Loan Costs PaymentsOfLoanCosts		usd
CY2020	enz	Salespurchases Of Marketable Securities SalespurchasesOfMarketableSecurities		usd
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
CY2022	us-gaap	Amount Of Dilutive Securities Stock Options And Restrictive Stock Units AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits		usd
CY2022	us-gaap	Revenues Revenues	107071000	usd
CY2021	us-gaap	Revenues Revenues	117731000	usd
CY2020	us-gaap	Revenues Revenues	76021000	usd
CY2022Q3	us-gaap	Noncurrent Assets NoncurrentAssets	39885000	usd
CY2021Q3	us-gaap	Noncurrent Assets NoncurrentAssets	41301000	usd
CY2022Q3	us-gaap	Reporting Unit Percentage Of Fair Value In Excess Of Carrying Amount ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount	1	pure
CY2022	enz	Product And Royalty Revenues ProductAndRoyaltyRevenues	32643000	usd
CY2021	enz	Product And Royalty Revenues ProductAndRoyaltyRevenues	30747000	usd
CY2020	enz	Product And Royalty Revenues ProductAndRoyaltyRevenues	26561000	usd
CY2022Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent		usd
CY2022Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill		usd
CY2021	us-gaap	Payments For Legal Settlements PaymentsForLegalSettlements		usd
CY2020	us-gaap	Payments For Legal Settlements PaymentsForLegalSettlements		usd
CY2020	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures		usd
CY2021	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures		usd
CY2020	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss		usd
CY2022Q3	enz	Finitelived Intangible Asset Net FinitelivedIntangibleAssetNet		usd
CY2022Q3	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities		usd
CY2021Q3	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities		usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments		pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations		pure
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations		pure
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations		pure
CY2022Q3	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree		usd
CY2022Q3	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour		usd
CY2022Q3	us-gaap	Finance Lease Liability Payments Due Year Five FinanceLeaseLiabilityPaymentsDueYearFive		usd
CY2022Q3	us-gaap	Finance Lease Liability Payments Due After Year Five FinanceLeaseLiabilityPaymentsDueAfterYearFive		usd
CY2022Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent		usd
CY2021Q3	enz	Current Portion Of Swiss CurrentPortionOfSwiss		usd
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0000316253

Files In Submission

Name	View Source	Status
0001213900-22-064086-index-headers.html	Edgar Link	pending
enz-20220731_cal.xml	Edgar Link	unprocessable
0001213900-22-064086-index.html	Edgar Link	pending
0001213900-22-064086.txt	Edgar Link	pending
0001213900-22-064086-xbrl.zip	Edgar Link	pending
enz-20220731.xsd	Edgar Link	pending
ex10ae_001.jpg	Edgar Link	pending
ex10ae_002.jpg	Edgar Link	pending
ex10ae_003.jpg	Edgar Link	pending
ex10ae_004.jpg	Edgar Link	pending
ex10ae_005.jpg	Edgar Link	pending
ex10ae_006.jpg	Edgar Link	pending
ex10ae_007.jpg	Edgar Link	pending
ex10ae_008.jpg	Edgar Link	pending
ex10ae_009.jpg	Edgar Link	pending
ex10ae_010.jpg	Edgar Link	pending
ex10ae_011.jpg	Edgar Link	pending
ex10ae_012.jpg	Edgar Link	pending
ex10ae_013.jpg	Edgar Link	pending
ex10ae_014.jpg	Edgar Link	pending
ex10ae_015.jpg	Edgar Link	pending
ex10ae_016.jpg	Edgar Link	pending
ex10ae_017.jpg	Edgar Link	pending
f10k2022ex10ae_enzobio.htm	Edgar Link	pending
f10k2022ex21_enzobio.htm	Edgar Link	pending
f10k2022ex23-1_enzobio.htm	Edgar Link	pending
f10k2022ex31a_enzobio.htm	Edgar Link	pending
f10k2022ex31b_enzobio.htm	Edgar Link	pending
f10k2022ex32a_enzobio.htm	Edgar Link	pending
f10k2022ex32b_enzobio.htm	Edgar Link	pending
f10k2022_enzobio.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
enz-20220731_def.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
enz-20220731_lab.xml	Edgar Link	unprocessable
enz-20220731_pre.xml	Edgar Link	unprocessable
f10k2022_enzobio_htm.xml	Edgar Link	completed
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ENZ
ENZO BIOCHEM INC Stock $enz

2022 Q4 Form 10-K Financial Statement

#000121390022064086 Filed on October 14, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ENZ ENZO BIOCHEM INC Stock $enz

2022 Q4 Form 10-K Financial Statement

#000121390022064086 Filed on October 14, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ENZ
ENZO BIOCHEM INC Stock $enz